Amgen [AMGN] vs Eli Lilly and [LLY] Detailed Stock Comparison

Amgen Inc.

NASDAQ
Loading...

Eli Lilly and Company

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amgen Inc. wins in 10 metrics, Eli Lilly and Company wins in 11 metrics, with 0 ties. Eli Lilly and Company appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amgen Inc. Eli Lilly and Company Better
P/E Ratio (TTM) 24.22 40.09 Amgen Inc.
Price-to-Book Ratio 21.46 31.01 Amgen Inc.
Debt-to-Equity Ratio 640.28 165.31 Eli Lilly and Company
PEG Ratio 0.22 0.79 Amgen Inc.
EV/EBITDA 13.97 26.61 Amgen Inc.
Profit Margin (TTM) 20.98% 31.67% Eli Lilly and Company
Operating Margin (TTM) 30.55% 44.90% Eli Lilly and Company
EBITDA Margin (TTM) 30.55% 44.90% Eli Lilly and Company
Return on Equity 106.10% 101.16% Amgen Inc.
Return on Assets (TTM) 7.93% 19.42% Eli Lilly and Company
Free Cash Flow (TTM) $8.10B $5.96B Amgen Inc.
Dividend Yield 3.30% 0.60% Amgen Inc.
1-Year Return 20.32% 38.28% Eli Lilly and Company
Price-to-Sales Ratio (TTM) 5.06 12.63 Amgen Inc.
Enterprise Value $232.21B $843.37B Eli Lilly and Company
EV/Revenue Ratio 6.32 12.94 Amgen Inc.
Gross Profit Margin (TTM) 69.84% 82.52% Eli Lilly and Company
Revenue per Share (TTM) $68 $73 Eli Lilly and Company
Earnings per Share (Diluted) $14.24 $22.94 Eli Lilly and Company
Beta (Stock Volatility) 0.47 0.50 Amgen Inc.
Short % of Float 2.60% 0.97% Eli Lilly and Company

Amgen Inc. vs Eli Lilly and Company Stock Performance Analysis

Loading Price Chart...

AMGN
LLY

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amgen Inc.-1.31%1.39%7.42%-4.29%7.75%6.99%
Eli Lilly and Company-0.32%-1.72%12.38%14.18%6.32%4.53%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amgen Inc.20.32%54.66%48.82%137.40%512.31%431.58%
Eli Lilly and Company38.28%153.07%418.42%1,433.98%2,935.09%1,988.48%

Performance & Financial Health Analysis: Amgen Inc. vs Eli Lilly and Company

MetricAMGNLLY
Market Information
Market Cap i$187.93B$821.31B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i2,431,7532,387,476
90 Day Avg. Volume i2,596,2912,777,749
Last Close$350.53$1,129.35
52 Week Range$267.83 - $391.29$623.78 - $1,182.73
% from 52W High-10.42%-4.51%
All-Time High$391.29 (Mar 02, 2026)$1,182.73 (Jun 08, 2026)
% from All-Time High-10.42%-4.51%
Growth Metrics
Quarterly Revenue Growth0.09%0.43%
Quarterly Earnings Growth1.13%0.51%
Financial Health
Profit Margin (TTM) i0.21%0.32%
Operating Margin (TTM) i0.31%0.45%
Return on Equity (TTM) i1.06%1.01%
Debt to Equity (MRQ) i640.28165.31
Cash & Liquidity
Book Value per Share (MRQ)$16.07$29.66
Cash per Share (MRQ)$16.94$8.14
Operating Cash Flow (TTM) i$9.96B$16.81B
Levered Free Cash Flow (TTM) i$7.50B$1.95B
Dividends
Last 12-Month Dividend Yield i3.30%0.60%
Last 12-Month Dividend i$12.18$6.23

Valuation & Enterprise Metrics Analysis: Amgen Inc. vs Eli Lilly and Company

MetricAMGN (Apr 24, 2026)LLY (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i24.2240.09
Forward P/E i14.7721.82
PEG Ratio i0.220.79
Price to Sales (TTM) i5.0612.63
Price to Book (MRQ) i21.4631.01
Market Capitalization
Market Capitalization i$187.93B$821.31B
Enterprise Value i$232.21B$843.37B
Enterprise Value Metrics
Enterprise to Revenue i6.3212.94
Enterprise to EBITDA i13.9726.61
Risk & Other Metrics
Beta i0.470.50
Book Value per Share (MRQ) i$16.07$29.66

Financial Statements Comparison: Amgen Inc. vs Eli Lilly and Company

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMGN (2025)LLY (2025)
Revenue/Sales i36.75B65.18B
Cost of Goods Sold i12.04B11.05B
COGS % of Revenue i32.8%17.0%
Gross Profit i24.71B54.13B
Gross Margin i67.2%83.0%
Research & Development i7.27B13.34B
Operating Income (EBIT) i9.08B29.70B
Operating Margin i24.7%45.6%
EBITDA i16.90B35.09B
EBITDA Margin i46.0%53.8%
Pre-Tax Income i8.98B25.73B
Pre-Tax Income % of Revenue i24.4%39.5%
Income Tax i1.27B5.09B
Income Tax % of Revenue i3.4%7.8%
Net Income (Profit) i7.71B20.64B
Profit Margin i21.0%31.7%

Balance Sheet & Liquidity Metrics

MetricAMGN (2025)LLY (2025)
Cash & Equivalents i9.13B7.27B
Total Current Assets i29.06B55.63B
Total Current Assets % of Revenue i79.1%85.3%
Total Current Liabilities i25.49B35.23B
Total Current Liabilities % of Revenue i69.4%54.0%
Long-Term Debt i50.01B40.87B
Long-Term Debt % of Revenue i136.1%62.7%
Total Shareholders Equity i8.66B26.54B
Retained Earnings i-25.11B24.47B
Retained Earnings % of Revenue i-68.3%37.5%
Property, Plant & Equipment i5.22B13.49B

Cash Flow Statement Comparison

MetricAMGN (2025)LLY (2025)
Operating Cash Flow i10.51B23.60B
Operating Cash Flow % of Revenue i28.6%36.2%
Capital Expenditures i-1.86B-7.84B
Free Cash Flow i8.10B5.96B
FCF Margin i22.0%9.2%
Debt Repayment i-5.00B-778.00M
Common Stock Repurchase i0-4.11B

Short Interest & Institutional Ownership Analysis

MetricAMGNLLY
Shares Short i13.98M7.70M
Short Ratio i5.432.73
Short % of Float i2.60%0.97%
Shares Outstanding i538.80M894.80M
Float Shares i537.62M890.99M
% Held by Insiders i0.22%0.17%
% Held by Institutions i85.36%84.77%
% Held by Public i14.42%15.06%

Dividend Analysis & Yield Comparison: Amgen Inc. vs Eli Lilly and Company

MetricAMGNLLY
Last 12-Month Dividend i$12.18$6.23
Last 12-Month Dividend Yield i3.30%0.60%
3-Year Avg Annual Dividend i$9.98$5.44
3-Year Avg Dividend Yield i0.77%0.18%
3-Year Total Dividends i$29.95$16.32
Ex-Dividend DateMay 15, 2026Feb 13, 2026